02.11.2023 • News
AstraZeneca Invests $245 Million in French Biotech Cellectis
Anglo-Swedish drugmaker AstraZeneca entered into a collaboration and investment agreement with Cellectis, a French clinical-stage biotechnology company, to accelerate the development of therapeutics across oncology, immunology and rare diseases.
